RAD52 and neoplasm: In a sub-cohort analysis of patients who received preoperative neoadjuvant therapy, low RAD52 expression was associated with worse DFS (p = 0.012; Figure 3D) and OS (p = 0.014; Figure 3F) in patients with LN-positive tumours, but no association with survival outcome was observed in patients with LN-negative tumours (DFS, p = 0.317; OS, p = 0.244; Figure 3C,E).